Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV pp65-specific T cells for CMV reactivation or disease after allogeneic stem cell transplantation
2010-024307-27Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2011
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytomegalovirus pp65-specific cytotoxic t lymphocytes in cytomegalovirus disease (CMV), sponsored by Leiden University Medical Center. Primary endpoint: Acute GvHD, death, and adverse events. Started Sep 2011; status: active.
02
Drugs
cytomegalovirus pp65-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2010-024307-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024307-27.